Catherine Skari
-
Feb- 2023 -22 FebruaryNews
SICKLE CELL DISEASE | Hydroxyurea Use Linked To Higher Rates Of Spleen Removal
The study’s findings also indicated that SCD children treated with hydroxyurea underwent splenectomy surgery at a significantly younger age compared…
Read More » -
17 FebruaryScientific Literature
Reduction in Vaso-Occlusive Events Following Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease
Hematopoietic stem cell transplantation (HSCT) is potentially curative for patients with sickle cell disease (SCD). Patients with stable donor engraftment…
Read More » -
15 FebruaryScientific Literature
Longitudinal Study of ICET-A on Glucose Tolerance, Insulin Sensitivity and β-cell Secretion in Eleven β-Thalassemia Major Patients With Mild Iron Overload
Background: Iron chelation therapy (ICT) is the gold standard for treating patients with iron overload, though its long-term effects are still…
Read More » -
14 FebruaryNews
COMING UP | Share Your Colours For Rare Disease Day 2023
A Few Words About Rare Diseases and the RDD2023 Campaign Rare Disease Day (RDD) is the official international awareness-raising campaign…
Read More » -
10 FebruaryScientific Literature
Association of Sickle Cell Disease With Severe Maternal Morbidity
Objective: To evaluate the association between sickle cell disease (SCD) and severe maternal morbidity (SMM) in a contemporary cohort of…
Read More » -
9 FebruaryNews
CLINICAL RESULTS | Roche Reports Positive Data for Crovalimab as Rare Blood Disease Treatment
PNH causes a patient’s red blood cells to break apart, resulting in a range of debilitating symptoms such as anaemia,…
Read More » -
Jan- 2023 -28 JanuaryScientific Literature
Juggling Between the Cost and Value of New Therapies: Does Science Still Serve Patient Needs?
Thalassaemia International Federation (TIF), representing the united voice of people with thalassaemia and their families globally, has been striving for…
Read More » -
26 JanuaryNews
TOP STORY | EMA Validates Vertex’s/CRISPR Submission Of Exa-Cel For β-Τhal And SCD
The Marketing Authorization Application (MAA) for exagamglogene autotemcel (exa-cel), marks the first regulatory submission in the EU for a…
Read More » -
23 JanuaryNews
COLD AGGLUTININ DISEASE | Enjaymo Improves Life Quality And Lessens Fatigue, According to Phase 3 Trial Results
These findings “further augment the primary efficacy outcomes of the placebo-controlled Phase 3 CADENZA study, demonstrating that in addition to…
Read More » -
23 JanuaryNews
IRON CONTROL | Disc Medicine And Mabwell Sign Deal For Licence To Antibodies Portfolio
Disc plans to initiate a phase 1 trial in healthy volunteers in the second half of 2023. MWTX-003 has the…
Read More »